Cargando…

Clinical Factors and Outcomes When Real-World Heart Teams Overruled STS Risk Scores in TAVR Cases

OBJECTIVES: This study was conducted to determine why heart teams recommended transcatheter aortic valve replacement (TAVR) versus surgical AVR (SAVR) for patients at low predicted risk of mortality (PROM) and describe outcomes of these cases. BACKGROUND: Historically, referral to TAVR was based pre...

Descripción completa

Detalles Bibliográficos
Autores principales: King, Jackson M., Black, Morgan T., Jin, Ruyun, Grunkemeier, Gary L., Reynolds, Branden R., Curtis, Brydan D., Hodson, Robert W., Strehl, Erika A., Gafoor, Sameer A., Forrester, Matthew D., Cox, Emily J., Ring, Michael E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252751/
https://www.ncbi.nlm.nih.gov/pubmed/35832534
http://dx.doi.org/10.1155/2022/9926423
_version_ 1784740339319308288
author King, Jackson M.
Black, Morgan T.
Jin, Ruyun
Grunkemeier, Gary L.
Reynolds, Branden R.
Curtis, Brydan D.
Hodson, Robert W.
Strehl, Erika A.
Gafoor, Sameer A.
Forrester, Matthew D.
Cox, Emily J.
Ring, Michael E.
author_facet King, Jackson M.
Black, Morgan T.
Jin, Ruyun
Grunkemeier, Gary L.
Reynolds, Branden R.
Curtis, Brydan D.
Hodson, Robert W.
Strehl, Erika A.
Gafoor, Sameer A.
Forrester, Matthew D.
Cox, Emily J.
Ring, Michael E.
author_sort King, Jackson M.
collection PubMed
description OBJECTIVES: This study was conducted to determine why heart teams recommended transcatheter aortic valve replacement (TAVR) versus surgical AVR (SAVR) for patients at low predicted risk of mortality (PROM) and describe outcomes of these cases. BACKGROUND: Historically, referral to TAVR was based predominately on the Society of Thoracic Surgeons (STS) risk model's PROM >3%. In selected cases, heart teams had latitude to overrule these scores. The clinical reasons and outcomes for these cases are unclear. METHODS: Retrospective data were gathered for all TAVR and SAVR cases conducted by 9 hospitals between 2013 and 2017. RESULTS: Cases included TAVR patients with STS PROM >3% (n = 2,711) and ≤3% (n = 415) and SAVR with STS PROM ≤3% (n = 1,438). Leading reasons for recommending TAVR in the PROM ≤3% group were frailty (57%), hostile chest (22%), severe lung disease (16%), and morbid obesity (13%), and 44% of cases had multiple reasons. Most postoperative and 30-day outcomes were similar between TAVR groups, but the STS PROM ≤3% group had a one-day shorter length of stay (2.5 ± 3.4 vs. 3.5 ± 4.7 days; p ≤ 0.001) and higher one-year survival (91.6% vs. 86.0%, p=0.002). In patients with STS PROM ≤3%, 30-day mortality was higher for TAVR versus SAVR (2.0% vs. 0.6%; p < 0.001). CONCLUSIONS: Heart teams recommended TAVR in patients with STS PROM ≤3% primarily due to frailty, hostile chest, severe lung disease, and/or morbid obesity. Similar postoperative outcomes between these patients and those with STS PROM >3% suggest that decisions to overrule STS PROM ≤3% were merited and may have reduced SAVR 30-day mortality rate.
format Online
Article
Text
id pubmed-9252751
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-92527512022-07-12 Clinical Factors and Outcomes When Real-World Heart Teams Overruled STS Risk Scores in TAVR Cases King, Jackson M. Black, Morgan T. Jin, Ruyun Grunkemeier, Gary L. Reynolds, Branden R. Curtis, Brydan D. Hodson, Robert W. Strehl, Erika A. Gafoor, Sameer A. Forrester, Matthew D. Cox, Emily J. Ring, Michael E. J Interv Cardiol Research Article OBJECTIVES: This study was conducted to determine why heart teams recommended transcatheter aortic valve replacement (TAVR) versus surgical AVR (SAVR) for patients at low predicted risk of mortality (PROM) and describe outcomes of these cases. BACKGROUND: Historically, referral to TAVR was based predominately on the Society of Thoracic Surgeons (STS) risk model's PROM >3%. In selected cases, heart teams had latitude to overrule these scores. The clinical reasons and outcomes for these cases are unclear. METHODS: Retrospective data were gathered for all TAVR and SAVR cases conducted by 9 hospitals between 2013 and 2017. RESULTS: Cases included TAVR patients with STS PROM >3% (n = 2,711) and ≤3% (n = 415) and SAVR with STS PROM ≤3% (n = 1,438). Leading reasons for recommending TAVR in the PROM ≤3% group were frailty (57%), hostile chest (22%), severe lung disease (16%), and morbid obesity (13%), and 44% of cases had multiple reasons. Most postoperative and 30-day outcomes were similar between TAVR groups, but the STS PROM ≤3% group had a one-day shorter length of stay (2.5 ± 3.4 vs. 3.5 ± 4.7 days; p ≤ 0.001) and higher one-year survival (91.6% vs. 86.0%, p=0.002). In patients with STS PROM ≤3%, 30-day mortality was higher for TAVR versus SAVR (2.0% vs. 0.6%; p < 0.001). CONCLUSIONS: Heart teams recommended TAVR in patients with STS PROM ≤3% primarily due to frailty, hostile chest, severe lung disease, and/or morbid obesity. Similar postoperative outcomes between these patients and those with STS PROM >3% suggest that decisions to overrule STS PROM ≤3% were merited and may have reduced SAVR 30-day mortality rate. Hindawi 2022-06-25 /pmc/articles/PMC9252751/ /pubmed/35832534 http://dx.doi.org/10.1155/2022/9926423 Text en Copyright © 2022 Jackson M. King et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
King, Jackson M.
Black, Morgan T.
Jin, Ruyun
Grunkemeier, Gary L.
Reynolds, Branden R.
Curtis, Brydan D.
Hodson, Robert W.
Strehl, Erika A.
Gafoor, Sameer A.
Forrester, Matthew D.
Cox, Emily J.
Ring, Michael E.
Clinical Factors and Outcomes When Real-World Heart Teams Overruled STS Risk Scores in TAVR Cases
title Clinical Factors and Outcomes When Real-World Heart Teams Overruled STS Risk Scores in TAVR Cases
title_full Clinical Factors and Outcomes When Real-World Heart Teams Overruled STS Risk Scores in TAVR Cases
title_fullStr Clinical Factors and Outcomes When Real-World Heart Teams Overruled STS Risk Scores in TAVR Cases
title_full_unstemmed Clinical Factors and Outcomes When Real-World Heart Teams Overruled STS Risk Scores in TAVR Cases
title_short Clinical Factors and Outcomes When Real-World Heart Teams Overruled STS Risk Scores in TAVR Cases
title_sort clinical factors and outcomes when real-world heart teams overruled sts risk scores in tavr cases
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252751/
https://www.ncbi.nlm.nih.gov/pubmed/35832534
http://dx.doi.org/10.1155/2022/9926423
work_keys_str_mv AT kingjacksonm clinicalfactorsandoutcomeswhenrealworldheartteamsoverruledstsriskscoresintavrcases
AT blackmorgant clinicalfactorsandoutcomeswhenrealworldheartteamsoverruledstsriskscoresintavrcases
AT jinruyun clinicalfactorsandoutcomeswhenrealworldheartteamsoverruledstsriskscoresintavrcases
AT grunkemeiergaryl clinicalfactorsandoutcomeswhenrealworldheartteamsoverruledstsriskscoresintavrcases
AT reynoldsbrandenr clinicalfactorsandoutcomeswhenrealworldheartteamsoverruledstsriskscoresintavrcases
AT curtisbrydand clinicalfactorsandoutcomeswhenrealworldheartteamsoverruledstsriskscoresintavrcases
AT hodsonrobertw clinicalfactorsandoutcomeswhenrealworldheartteamsoverruledstsriskscoresintavrcases
AT strehlerikaa clinicalfactorsandoutcomeswhenrealworldheartteamsoverruledstsriskscoresintavrcases
AT gafoorsameera clinicalfactorsandoutcomeswhenrealworldheartteamsoverruledstsriskscoresintavrcases
AT forrestermatthewd clinicalfactorsandoutcomeswhenrealworldheartteamsoverruledstsriskscoresintavrcases
AT coxemilyj clinicalfactorsandoutcomeswhenrealworldheartteamsoverruledstsriskscoresintavrcases
AT ringmichaele clinicalfactorsandoutcomeswhenrealworldheartteamsoverruledstsriskscoresintavrcases